ÂÜÀòÂÒÂ×

Received his Ph.D. degree in molecular and cellular biology from the Mt. Sinai School of Medicine, New York. Dr. Ryaby was the Chief Scientific Officer (CSO) at Orthofix, a publicly traded medical device company located in Dallas, TX, from July 2013 to April 2020. At Orthofix he led the group conducting IDE clinical studies of Pulsed Electromagnetic Field technology for treatment of knee osteoarthritis and rotator cuff repair. Prior to and now after Orthofix, Dr. Ryaby serves as an independent consultant advising on preclinical, clinical and regulatory programs for biotech, medical device, and pharmaceutical companies. Dr. Ryaby served as Vice President (VP) of Research and Clinical Affairs for musculoskeletal applications at Mesoblast and VP of Biologics at MCRA. In the past he also served as Senior VP of Research and Clinical Affairs and CSO at OrthoLogic Corp in Tempe, AZ where he led the development of the CMF technology for spine fusion and nonunions (now owned by DJO Global) and the TP508 and AZX100 peptide therapeutic development programs in orthopedic and wound repair indications. He also served as Adjunct Professor of Bioengineering at Arizona State University. His current research interests are the biological effects and clinical applications of biophysical stimuli, the biology and clinical applications of novel biotherapeutics and adult stem cells in musculoskeletal tissue repair, and application of advanced imaging techniques for musculoskeletal tissue repair.